Fennec Pharmaceuticals Inc. (FENC) stock
FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3088% above fair value
$13.58+0.82 (+6.43%)
Close on Nov 17, 2026Market cap $476.21MP/E –Yield –
Fennec Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Fennec Pharmaceuticals's price to sales ratio was 6.3× on Nov 11, 2026, against 5.9× a year earlier. Over the last 3 years it ranged from 2.4× to 14.1×, with a median of 6.1×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 6.3× | +0.7 |
| 2025 | Dec 31, 2025 | 5.6× | +2.1 |
| 2024 | Dec 31, 2024 | 3.5× | – |
See a number that looks wrong?